Kyntheum (Brodalumab)

Brodalumab, the active ingredient in Kyntheum, binds to interleukin‑17 receptor A, blocking the activity of several IL‑17 cytokines. This interruption stops the inflammatory signaling cascade that leads to keratinocyte overgrowth and plaque formation, thereby reducing the signs and symptoms of psoriasis.

The dosing regimen for Kyntheum is determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response to therapy. The prescriber will decide the exact amount, frequency, and duration of treatment according to approved guidelines.

The safety of Kyntheum in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, so clinicians must weigh potential benefits against possible risks and discuss these considerations with the patient before initiating therapy.

To order Kyntheum, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Kyntheum (brodalumab) targets the IL‑17 receptor, whereas other biologics may target IL‑17A (secukinumab, ixekizumab) or TNF‑α (adalimumab, etanercept). By blocking the receptor, brodalumab can inhibit multiple IL‑17 cytokines simultaneously, which may offer a broader anti‑inflammatory effect in some patients, though individual response varies.

Kyntheum should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. If the product reaches room temperature, it may be used within the time frame specified in the product labeling.

Kyntheum is supplied as a 210 mg/1 mL solution for subcutaneous injection. The medication is injected under the skin, typically in the abdomen, thigh, or upper arm, by a healthcare professional or a trained patient following the prescriber’s instructions.

The most serious risks include the potential for suicidal ideation or behavior, severe infections, allergic reactions such as anaphylaxis, and possible exacerbation of inflammatory bowel disease. Patients should be monitored closely for mood changes, signs of infection, and any gastrointestinal symptoms.

Kyntheum is contraindicated in patients with known hypersensitivity to brodalumab or any of its excipients. It should also be avoided in individuals with active serious infections, uncontrolled inflammatory bowel disease, or those who are pregnant without a clear risk‑benefit assessment.